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Trichomonas vaginalis infection is estimated to be the most widely prevalent nonviral sexually transmitted
infection in the world. Wet-mount microscopy is the most common diagnostic method, although it is less
sensitive than culture. The OSOM Trichomonas Rapid Test (Genzyme Diagnostics, Cambridge, Mass.) (re-
ferred to here as OSOM) is a new point-of-care diagnostic assay for T. vaginalis that uses an immunochro-
matographic capillary flow (dipstick) assay and provides results in 10 min. The purpose of this study was to
determine the test characteristics of OSOM compared to those of a composite reference standard (CRS)
comprised of wet-mount microscopy and T. vaginalis culture. This multicenter cross-sectional study enrolled
sexually active women >18 years of age who presented with symptoms of vaginitis, exposure to T. vaginalis, or
multiple sexual partners. Vaginal-swab specimens were obtained for T. vaginalis culture, wet mount, and rapid
testing. The prevalence of T. vaginalis in this sample was 23.4% (105 of 449) by the CRS. The sensitivity and
specificity of OSOM vaginal-swab specimens were 83.3 and 98.8%, respectively, while wet mount had a
sensitivity and specificity of 71.4 and 100%, respectively, compared to the CRS. OSOM performed significantly
better than wet mount (P  0.004) and detected T. vaginalis in samples that required 48 to 72 h of incubation
prior to becoming culture positive. The performance of the rapid test was not affected by the presence of
coinfections with chlamydia and gonorrhea. The OSOM Trichomonas Rapid Test is a simple, objective test that
can be expected to improve the diagnosis of T. vaginalis, especially where microscopy and culture are
unavailable.
Trichomonas vaginalis infection is estimated to be the most
widely prevalent nonviral sexually transmitted infection (STI)
in the world. Weinstock et al. estimated that 7.4 million new
cases of T. vaginalis infection occurred in 2000 in the United
States, compared to 2.8 million cases of Chlamydia trachomatis
infection and 718,000 cases of Neisseria gonorrhoeae infection
(16). The prevalence of T. vaginalis is likely to be underesti-
mated because there are no guidelines for T. vaginalis screen-
ing of women, and clinicians often rely upon insensitive diag-
nostic methods.
The most common method of T. vaginalis detection is wet-
mount microscopy. Although this technique is inexpensive and
provides immediate results, it is a subjective test that requires
clinical experience and access to a microscope. Even in the
hands of trained observers, the wet mount is only 36 to 75%
sensitive compared to culture (17).
The present “gold standard” for the diagnosis of T. vaginalis
is culture. Selective media for culture include Diamond’s, Tri-
chosel, and InPouch TV (BioMed Diagnostics, San Jose,
Calif.). No single culture appears to have 100% sensitivity for
T. vaginalis infection. When all three media are inoculated with
a known-positive sample, all of the culture media are compa-
rable (85 to 87% sensitive and 100% specific), when the gold
standard is defined as growth of T. vaginalis in at least one of
the three media (1, 11). The advantages of the InPouch culture
include its ease of use; the combination of specimen transport,
growth, and evaluation; and its long shelf life. However, it
requires on-site incubators, microscopes, and 24 to 120 h for
final results. The only commercially available product is a nu-
cleic acid probe test (AffirmVPIII; Becton Dickinson, Sparks,
Md.). It has excellent sensitivity (90%) but requires 45 min for
results, is more expensive than culture, and is classified as a
moderately complex test (4, 6). Other nucleic acid amplifica-
tion techniques for T. vaginalis available for research studies
appear to have excellent sensitivity and specificity but are not
applicable for point-of-care use (7). One immunochromato-
graphic monoclonal-antibody-based detection system (Xeno-
Strip-Tv; Xenotope Diagnostics, Inc., San Antonio, Tex.) has
demonstrated a sensitivity of 78.5 to 90% when performed on
vaginal-swab samples, but it requires up to 20 min to read (9,
12).
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The OSOM Trichomonas Rapid Test (Genzyme Diagnos-
tics, Cambridge, Mass.) is a new point-of-care diagnostic assay
for T. vaginalis. Like the XenoStrip-Tv, it is an immunochro-
matographic capillary flow (dipstick) assay. The test employs a
pair of murine monoclonal antibodies, one immobilized on the
surface of the dipstick and the other conjugated to particles
and dried onto the dipstick. In the present study, we deter-
mined the sensitivity and specificity of the OSOM Trichomo-
nas Rapid Test compared to those of a composite reference
standard (CRS) of wet-mount microscopy and culture per-
formed on two types of samples: vaginal swabs and saline
solution remaining after wet-mount microscopy.
MATERIALS AND METHODS
Study population. Sexually active women 18 years of age or older presenting
with signs and symptoms of vaginosis or vaginitis or due to exposure to T.
vaginalis through an infected partner or high-risk behavior were enrolled in a
prospective, cross-sectional, multicenter study. High-risk behavior was defined as
two or more sexual partners reported within the last 30 days. Patients were also
admitted into the study if they presented for a follow-up visit because of a
previously diagnosed T. vaginalis infection and were within 30 days posttreat-
ment. Study clinicians at eight participating sites informed eligible patients about
the study and enrolled those who consented to participate. The study was ap-
proved by the institutional review board at each research center. Enrollment
occurred between June and October 2003, ending when the target sample size of
100 T. vaginalis-positive patients had been reached.
Collection of specimens. Following a history and physical examination, the
clinicians obtained three vaginal samples from each patient by swabbing the
vaginal vault. The clinicians were asked to vary the order in which they obtained
the vaginal swabs to prevent sampling bias. One swab was placed in a plastic tube
containing 0.5 ml of saline and used immediately for wet-mount microscopy.
Another swab was used to immediately inoculate an InPouch TV culture device.
A third swab was placed in a 12- by 75-mm dry plastic tube and stored frozen at
or below 20°C. In addition, the remainder of the saline solution used to prepare
the wet mount (wet-mount saline) was also stored frozen. Dry swabs and wet-
mount saline samples without identification were shipped to the Genzyme Cor-
poration on dry ice by overnight courier at scheduled intervals. The specimens
were stored frozen for up to 17 weeks prior to being tested. Additional cervical
samples were obtained for detection of other sexually transmitted diseases
(STDs), such as C. trachomatis and N. gonorrhoeae infections, according to the
local standard of care. At six sites, every enrollee was tested for N. gonorrhoeae
infection by culture or Pace2 (GenProbe, San Diego, Calif.). At five sites, every
enrollee was tested for C. trachomatis infection by Pace2 or ProbetecET (Becton
Dickinson, Sparks, Md.).
Laboratory methods. Wet-mount microscopy was performed according to the
standard of care at each site. In general, a swab containing the vaginal sample
was placed in a 12- by 75-mm plastic tube containing 0.5 ml of saline. Clinicians
or laboratory technicians transported the swab to an in-office laboratory. After
vigorous mixing of the swab in the saline, the swab was removed and depressed
onto a clean, dry microscope slide to express a small amount of liquid. A
coverslip was placed over the sample, and the slide was examined with a bright-
field microscope by the clinician or laboratory technician within 10 min of
collection. For culture, the InPouch TV system was performed according to the
manufacturer’s instructions. Briefly, the InPouch TV system was inoculated by
placing a vaginal-swab sample into the upper chamber, mixing the swab in the
medium, and then discarding the swab and sealing the pouch. The contents of the
upper chamber were immediately expressed into the lower chamber, and the
pouch was sealed and placed into a 37°C incubator. The culture was then read in
the same manner as a wet mount for up to 5 days or until it was positive.
In order to provide standardization for this research study, the OSOM
Trichomonas Rapid Test was performed on batched samples in the Genzyme
research laboratory over a 12-day testing period. Operators were blinded to
wet-mount and T. vaginalis culture results. Swab specimens were allowed to
warm to room temperature before testing began. Using the supplied dropper top,
0.5 ml of sample buffer was added to flexible plastic test tubes supplied with the
kit. Swabs containing vaginal specimens were placed in the tubes containing
sample buffer, mixed vigorously, and allowed to sit for 1 min. Excess liquid was
removed from the swabs by squeezing the sides of the test tubes, and the swabs
were removed and discarded. An OSOM Trichomonas Rapid Test stick was
placed in each tube containing the buffer-sample mixture, and results were read
at 10 min. A positive result was indicated by the presence of a blue test line along
with a red control line, whereas in a negative result, only a red control line was
visible. If no red control line was visible, the test result was considered invalid. To
test the wet-mount saline solution, a clean swab was inserted into the thawed
wet-mount saline and placed in a flexible plastic test tube containing sample
buffer, and the test was performed as previously described.
Analysis. The results of OSOM tests of the vaginal swab and the wet-mount
saline were compared individually to those of T. vaginalis culture, wet mount, and
the CRS. The CRS was defined as positive if there was a positive result by either
wet mount or culture. Samples were classified as negative if both wet mount and
culture were negative. Comparisons of the difference in sensitivities between wet
mount and OSOM were done using McNemar’s test for paired samples. All
analyses were performed using Excel (Microsoft Corp., Redmond, Wash.), JMP
(SAS Institute, Cary, N.C.), and Stata version 7 (StataCorp, College Station,
Tex.).
RESULTS
A total of 511 patients were enrolled in the study at seven
sites throughout the United States. One site was excluded from
the study because all 62 swabs collected for the rapid test were
inadvertently discarded by the site. For the remaining 449
patients enrolled, 439 vaginal swabs were received for OSOM
testing; 2 gave invalid test results, leaving 437 for analysis. Four
hundred forty-eight samples of wet-mount saline were received
for OSOM testing (1 gave invalid test results, leaving 447 for
analysis). Wet mounts were read for 449 patients, and 405
vaginal-swab cultures were read for 5 days (or until they were
positive). Additional testing was performed for N. gonorrhoeae
in 415 patients and C. trachomatis in 315 patients.
Nearly all subjects (439 of 449; 98%) who enrolled presented
to a study site with signs and symptoms of vaginitis or vaginosis.
Among these 439 symptomatic subjects, 95 (22%) also re-
ported high-risk behavior (i.e., 2 sex partners in the last 30
days), and 23 (5%) also reported contact with an infected
partner. Four subjects met all three enrollment criteria. Four
subjects presented for a follow-up visit with signs and symp-
toms. Ten subjects did not exhibit signs or symptoms; six were
eligible due to high-risk behavior alone, and four had an in-
fected partner.
Overall, the prevalence of T. vaginalis in this population was
23.4% (105 of 449) by the CRS and was similar across sites
(range, 17.2 to 28.7%). African-Americans were the predom-
inant racial group represented (76%), followed by Caucasian
(21%), Native American (2.7%), other (2.2%), Hispanic (4%),
and Asian (0.4%). Some patients listed more than one racial
background, resulting in a total greater than 100%. The mean
age for all patients was 28 years old (range, 18 to 61 years old).
The prevalence of T. vaginalis was higher in women over age 30
than in those aged 18 to 29 (31.3 versus 19.2%; 2  8.2; P 
0.004).
The study results are displayed in Fig. 1 and Table 1. In
comparison to the CRS, the sensitivity and specificity of
OSOM were 83.3 and 98.8%, respectively, while wet mount
was 71.4% sensitive. The sensitivity of the rapid test was sta-
tistically superior to that of wet mount (P  0.004). By defini-
tion, the specificity of wet mount relative to the CRS is 100%
(Table 1). Compared to culture alone, OSOM was 83.5% sen-
sitive and 99.0% specific, whereas wet mount was 70.0% sen-
sitive and 99.7% specific. The positive and negative predictive
values of the rapid test were 95.5 and 95.1%, respectively.
Among the specimens tested by rapid test, culture, and wet
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mount, OSOM detected 11 positive samples missed by wet
mount (Table 2). The more favorable sensitivity of the rapid
test compared to wet mount is due in part to the ability of
OSOM to detect T. vaginalis in samples that did not yield a
positive culture for 48 to 72 h. Both the rapid test and wet
mount missed one specimen that became positive after 4 days
of culture and one specimen that became positive after 5 days
of culture.
Because wet-mount microscopy is inexpensive and can de-
tect other infections, such as bacterial vaginosis and yeast, we
examined the performance of wet mount and the rapid test for
a single vaginal sample. Wet-mount saline tested with OSOM
demonstrated a sensitivity of 75.2% and a specificity of 98.5%
compared to the CRS, similar to the test characteristics of wet
mount compared to those of the CRS. However, the rapid test
of wet-mount saline detected an additional 27% (8 of 30) of T.
vaginalis infections that were wet mount negative but culture
positive.
To determine if coinfections had an effect on the rapid test,
we evaluated the sensitivity and specificity of OSOM compared
to those of the CRS stratified by coinfection status. To do this,
we looked at the subset of subjects that were tested for both N.
gonorrhoeae and T. vaginalis (n  415) and at the subset tested
for both C. trachomatis and T. vaginalis (n  315). In patients
with a concurrent C. trachomatis infection, the sensitivity of the
rapid test was 85.7% compared to 80.9% in those with a neg-
ative C. trachomatis test. Similarly, in patients coinfected with
N. gonorrhoeae, the OSOM sensitivity was 76.9% compared to
83.7% in those with a negative N. gonorrhoeae test. The spec-
ificity of the rapid test did not differ significantly by C. tracho-
matis infection status (100 versus 98%) or by N. gonorrhoeae
infection status (94.7 versus 99%). Due to the small numbers,
Bayesian analysis was performed to test the hypothesis that the
sensitivity and specificity did not differ by 10%. These differ-
ences were not statistically significant.
DISCUSSION
Historically, T. vaginalis has been viewed as a nuisance in-
fection that is primarily associated with genitourinary symp-
toms. It has also been considered a biological marker for high-
risk sexual behavior; thus, the detection of T. vaginalis would
trigger an evaluation for other pathogens. While T. vaginalis is
associated with sexual risk behavior and other STIs, it is now
considered an important independent pathogen. Multiple
studies have linked T. vaginalis infection to significant and
costly adverse health outcomes, such as pelvic inflammatory
disease (13, 14), the acquisition of human immunodeficiency
virus (5, 10), human immunodeficiency virus shedding (7), and
cervical cancer (15, 18, 19).
The majority of clinicians who presently test women for T.
vaginalis infection rely upon insensitive diagnostic methods,
such as wet mount, and asymptomatic women are seldom
tested at all. Although wet mount is the standard of care, it is
FIG. 1. Study flow diagram. TV, T. vaginalis.
TABLE 1. Performance of OSOM Trichomonas Rapid Test performed on vaginal swabs, wet mount alone, and OSOM Trichomonas Rapid
Test performed on wet-mount saline compared to CRS for the detection of T. vaginalis











b (%) NPVc (%)
OSOM swab (437) 85 4 17 331 83.3 (76–91) 98.8 (98–100) 95.5 95.1
Wet mount (449) 75 0 30 344 71.4 (63–80) NAd 100 92.0
OSOM salinee (447) 79 5 26 337 75.2 (67–84) 98.5 (97–100) 94.0 92.9
a CI, confidence interval.
b PPV, positive predictive value.
c NPV, negative predictive value.
d NA, not applicable (set at 100%).
e Saline from wet-mount preparation tested with OSOM.




No. of specimens positive by:
Culture OSOM Wet mount
1 76 73 69
2 13 6 1
3 6 2 0
4 1 0 0
5 1 0 0
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only 60% sensitive compared to culture (17). In many health
care settings, the lack of an experienced microscopist precludes
accurate detection of T. vaginalis. In some settings, the wet
mount is transported to the microbiology laboratory and read
by technicians after a significant time delay. The sensitivity of
wet-mount microscopy for detecting T. vaginalis declines sub-
stantially with even relatively short time intervals between col-
lection and examination (8). Where wet mount is available, the
appropriate T. vaginalis test for wet-mount-negative subjects
has not been delineated. We have demonstrated that OSOM
can be used on saline solution after a traditional wet mount is
performed and can identify T. vaginalis not detected by wet
mount.
In this study, T. vaginalis was common (23.4%) in sexually
active women presenting with signs and symptoms of vaginitis.
Consistent with previous reports (2, 3), the prevalence of T.
vaginalis did not decrease with age, as is seen with other STDs,
such as C. trachomatis and N. gonorrhoeae infections. Though
women over age 30 constituted one-third of our sample, they
contributed almost one-half (47%) of all T. vaginalis infections.
Symptomatic women over age 30 may be a target group for T.
vaginalis testing.
Since the OSOM rapid test is a point-of-care test, it would
enhance contact tracing in a difficult-to-reach population. As a
result, the test could have an important impact on individual,
as well as societal, consequences of untreated STDs. In addi-
tion, this rapid test is projected to cost significantly less than
culture and nucleic acid amplification methods and approxi-
mately the same as wet mount when cost estimates are based
on a technician’s time.
The limitations of this study are that the OSOM test was
performed on frozen samples in batches in a research setting.
However, the manufacturer’s data demonstrated that freezing
and transport of specimens did not appreciably alter the test
characteristics (T. Pisani [Genzyme Diagnostics], personal
communication), and they have been used for other assays
(12). Our patient population was at high risk for STIs in gen-
eral, and the results may not be comparable in another setting.
Further studies are needed to confirm our findings in other
patient groups and in clinical sites to assess user variability.
We demonstrated that the OSOM test is more sensitive than
wet mount for detecting T. vaginalis in a research setting with
expert microscopists. It requires less technical expertise and
time than T. vaginalis culture. Test performance was not af-
fected by the presence of other pathogens. OSOM can detect
T. vaginalis in samples that have a lower organism load and
that require longer incubation time in culture before being
classified as positive. When performed on wet-mount saline,
the rapid test detected several culture-positive samples that
were wet mount negative and thus may be a useful adjunct test
for wet-mount-negative subjects where culture is unavailable.
The new OSOM rapid test is an immunochromatographic
capillary flow (dipstick) assay that is simple to perform and
objective and can provide results in 10 min, so it may be
applied as a point-of-care test. Thus, it will be an important
addition to the repertoire of techniques available for T. vagi-
nalis detection, especially for facilities without access to a mi-
croscope or incubator and in settings where difficult patient
follow-up makes point-of-care testing attractive.
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